Zacks Investment Research
19 Jun 2026, 12:41 UTC · 13w ago
Verdict
Headline takes no side. We score ATRC +0.80 across four claims — strongly bullish.
+0.80strongly bullish
More positive than 84% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
AtriCure reiterated its long-term goal of reaching $1 billion in revenue by 2030 during the Goldman Sachs Global Healthcare Conference.
So whatLong-term revenue targets provide a growth roadmap that generally supports higher valuation multiples.
More positive than 76% of claims this week
AtriCure reported accelerated enrollment in its BoxX-NoAF clinical trial, which may substantially broaden its addressable market.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
More positive than 62% of claims this week
AtriCure is expected to post quarterly earnings of $0.03 per share, representing a year-over-year increase of 250%.
More positive than 49% of claims this week
The consensus EPS estimate for AtriCure has remained unchanged over the last 30 days.
More negative than 66% of claims this week
Which stocks this story touches
More positive than 84% of ticker scores this week
Shares rallied 6.2% due to renewed investor optimism and positive long-term growth prospects discussed at a conference.
More positive than 71% of ticker scores this week
Shares finished the last trading session 4.1% higher and have returned 10.2% over the past month.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
+102.5%
Price agrees with the score
$58.32 vs $28.80 close before publication (Jun 18) · not market-adjusted
ATRC chart →